Natale Imaz-Ayo

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 170 citations · Full text

T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19

Olatz Zenarruzabeitia, Gabirel Astarloa-Pando, Iñigo Terrén et al. · Frontiers in Immunology · 2021 · 63 citations · Full text

Clinical Immunology, Adaptive Immune System, Immunology +17

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Júlia Corominas, Carme Garriga, Antoni Prenafeta et al. · The Lancet Regional Health - Europe · 2023 · 31 citations · Full text

Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a population‐based program: A nested case‐control study

Eunate Arana‐Arri, Natale Imaz-Ayo, Mari Jose Fernández et al. · United European Gastroenterology Journal · 2018 · 25 citations · Full text